Navigation Links
Mylan Secures an Additional $300 Million of Committed Financing
Date:2/21/2012

PITTSBURGH, Feb. 21, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a facility agreement with a syndicate of banks to securitize up to $300 million of U.S. accounts receivable. The facility is committed and has a maturity of three years. The interest rate on any outstanding borrowings will be more than 100 basis points lower than the rate on the company's secured credit facilities.

Mylan Chief Financial Officer John Sheehan said: "We are pleased to have entered into this facility as it builds on our secured credit facility refinancing executed in November of last year and further serves to lower our weighted average borrowing costs. Today, Mylan has $1.55 billion of available committed financing through our secured credit and receivables financing facilities, providing the company with substantial operating flexibility."

Any amounts outstanding under the facility will be recorded as a secured loan and the receivables underlying any borrowings will continue to be included in the company's consolidated balance sheets.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
(Date:7/24/2014)... shows that incisionless transcatheter aortic valve replacement (TAVR) ... percent and has no impact on post-operative vascular ... which requires an incision in the groin. The ... of Circulation: Cardiovascular Interventions . , TAVR ... a traditional open-heart surgical approach. It is a ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
(Date:7/24/2014)... Angeles, CA (PRWEB) July 24, 2014 On ... loved ones will descend upon the Embassy Suites LAX North ... Conference hosted by DiabetesSisters and the first time it has ... first time for the organization to open the entire event ... As the only conference of its kind worldwide for women ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Human semen is ... microbes might have a role to play in both HIV ... that bacteria in semen -- the "microbiome" -- play a ... by infected men. They say the findings point to possible ... study couldn,t prove that the bacteria was causing changes in ...
Breaking Medicine News(10 mins):Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Bacteria in Semen May Affect HIV Transmission, Levels: Study 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: